Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial
暂无分享,去创建一个
G. Mancia | A. Zanchetti | M. Bond | M. Safar | B. Magnani | J. Reid | L. Hansson | K. Rahn | M. Hennig | J. Rodicio | A. Neiss | C. Dal palù | P. Rizzini | L. Eckes
[1] A. Zanchetti. The antiatherogenic effects of antihypertensive treatment: Trials completed and ongoing , 2001, Current hypertension reports.
[2] L. Ghiadoni,et al. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients , 2001, Journal of hypertension.
[3] A. Simon,et al. Differential Effects of Nifedipine and Co-Amilozide on the Progression of Early Carotid Wall Changes , 2001, Circulation.
[4] G. Berglund,et al. Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) , 2001, Circulation.
[5] S. Yusuf,et al. Effects of Ramipril and Vitamin E on Atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) , 2001, Circulation.
[6] C. Zancanaro,et al. The calcium‐channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE‐deficient mouse , 2000, Journal of hypertension.
[7] Michael E. Miller,et al. Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events , 2000, Circulation.
[8] John S. Scott,et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. , 2000, Journal of the American College of Cardiology.
[9] A. Folsom,et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. , 2000, American journal of epidemiology.
[10] A. Zanchetti,et al. Baseline reproducibility of B‐mode ultrasonic measurement of carotid artery intima – media thickness: the European Lacidipine Study on Atherosclerosis (ELSA) , 2000, Journal of hypertension.
[11] G. Gaviraghi,et al. Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells. , 1999, Journal of hypertension.
[12] R. Kronmal,et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.
[13] G. Gaviraghi,et al. Oxidized low‐density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine , 1998, Journal of hypertension.
[14] A. Zanchetti,et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long‐term randomized treatment with either verapamil or chlorthalidone on carotid intima‐media thickness , 1998, Journal of hypertension.
[15] Giuseppe Mancia,et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis , 1998, Journal of hypertension.
[16] R H Selzer,et al. The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events , 1998, Annals of Internal Medicine.
[17] Arno W. Hoes,et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. , 1997, Circulation.
[18] M. Rocco,et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. , 1996, JAMA.
[19] E. Donetti,et al. Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits , 1996, British journal of pharmacology.
[20] J. Salonen,et al. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. , 1993, Circulation.
[21] A. Zanchetti. The antiatherogenic effects of antihypertensive drugs: experimental and clinical evidence. , 1992, Clinical and experimental hypertension. Part A, Theory and practice.
[22] J. Ware,et al. Random-effects models for longitudinal data. , 1982, Biometrics.